人尿激肽原酶治疗急性脑梗死临床疗效观察

Clinical observation of human urinary kallikrein in patients with acute cerebral infarction

目的探讨人尿激肽原酶治疗急性脑梗死的疗效及其作用机制。方法将临床确诊的120例急性脑梗死患者随机分为实验组和对照组,对照组采用静滴丹参川芎嗪10mL,qd和奥扎格雷钠80mg,qd治疗,实验组采用静滴丹参川芎嗪10mL,qd和人尿激肽原酶0.15PNAU。治疗前后采用NIHSS评分、改良mRS量表评定神经功能缺损程度,检测治疗前后血压及血尿常规、血糖、血脂、肝肾功能变化,并详细记录不良反应。结果实验组和对照组患者治疗后的美国国立卫生研究院卒中量表(NIHSS)评分和mRS指数均有改善,但2组间比较实验组总体疗效明显优于对照组,差异具有统计学意义(P<0.05)。2组治疗过程中实验组1例患者出现轻微消化道症状,1例合并体位性低血压。结论人尿激肽原酶治疗急性脑梗死具有明显临床疗效,且较安全。

Objective To observe the efficacy and safety of urinary kallikrein in treating patients with acute cerebral infarction.Methods One hundred and twenty patients with acute cerebral infarction were randomized into two groups;the patients in treatment group（60 cases） received human urinary kallikrein 0.15 PNAU once a day for 10 days and ligustrazine hydrochloride injection 10 mL intravenously once a day,while the patients in control group（60 cases） received ligustrazine hydrochloride injection 10 mL intravenously once a day and sodium ozagrel 80 mg intravenously once a day.NIHSS and mRS were adopted to evaluate the clinical effect and the recovery of neurological functions before and after treatment.Simultaneously blood pressure,routine blood and urine,biochemical analysis results were examined.Results There was a significant decrease of NIHSS,mRS scores after the treatment in both groups（P0.01）,but NIHSS and mRS scores decreased more obviously in treatment group than that in control group（P0.05）.During the treatment,only one patient suffered from mild hunger sensation and one patient suffered from hypotension.Conclusion Human urinary kallikrein injection is an effective and safe drug in improving cerebral functions in patients with acute cerebral infarction.